Category: Data


New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients

Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco Burzotta and colleagues on data from the Roma-Verona Registry. This study examined the long-term outcomes of complex high-risk patients with multivessel disease who were considered unsuitable for surgery and received an Impella-supported Protected PCI. Dr. Burzotta and … Continue reading “New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients”

Use of Impella® Devices During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury

Patients undergoing complex coronary revascularization are at risk for periprocedural and postprocedural acute kidney injury (AKI), a complication which correlates with an increased risk of death, major bleeding, and myocardial infarction (MI).1 A reduction in cardiac output and renal hypoperfusion, which in turn leads to a decrease in glomerular filtration rate, may partly explain the increased risk for AKI during high-risk percutaneous coronary intervention (HRPCI).1Currently, there are few published studies which examine the impact of micro-axial percutaneous left ventricular assist devices on AKI in patients undergoing HRPCI. Continue readingUse of Impella® Devices During High-Risk PCI is Associated with Reduced Occurrence of Acute Kidney Injury

IABP vs Impella®: Incidence of Bleeding and Vascular Complications

Key Takeaways Patients undergoing high-risk PCI often require additional hemodynamic support, particularly with the help of ventricular assist devices. There is no significant difference between Impella 2.5® and IABP in terms of bleeding risk and vascular complications. High-risk patients with acute coronary syndrome (ACS) often require additional cardiac support during a protected percutaneous coronary intervention … Continue reading “IABP vs Impella®: Incidence of Bleeding and Vascular Complications”

New Study Finds Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention

Specialist Opinion with Dr. Seth Bilazarian A new retrospective, single-center study published in Circulation Research finds use of hemodynamic support with Impella 2.5® heart pump during high-risk percutaneous coronary intervention (HRPCI) can reduce the risk of acute kidney injury (AKI) even when those patients had preexisting kidney disease and low ejection fraction (EF). The new … Continue reading “New Study Finds Impella® Heart Pump Reduces Injury to Kidneys During High-Risk Percutaneous Coronary Intervention”

The Benefit of Impella® Support During Protected PCI for Revascularization

Drs. John Lasala, Bill O’Neill, Jeff Moses, and Bill Lombardi explain the benefit of Impella support during Protected PCI for revascularization.

Impella 2.5 and Impella CP are now approved by the FDA as safe and effective for use during high-risk PCI procedures. Learn more about the data and the clinical guidelines that support the approval. Additionally, learn how to identify patients who can benefit from Protected PCI and revascularization. Tune into this valuable conversation! Chapters include:
  • Maintaining Hemodynamic stability during high-risk PCI
  • Complete Revascularization is the Therapeutic Goal
  • Clinical Outcomes with PCI
Continue readingThe Benefit of Impella® Support During Protected PCI for Revascularization

Dr. George W. Vetrovec Discusses Completeness of Revascularization

Data is emerging to support the notion that leaving patients behind with un-revascularized territories may be a risk to be discussed with patients. The key challenge is to completely revascularize patients. Dr. George Vetrovec, Professor Emeritus of the Virginia Commonwealth University, shares his thoughts with ProtectedPCI.com’s Dr. Seth Bilazarian in the podcast below covering completeness … Continue reading “Dr. George W. Vetrovec Discusses Completeness of Revascularization”